« Home Research About Contact Us

Neurosearch -USA

Change the future with us

Parkinson's
Disease
Multiple
sclerosis
Alzheimer's
Disease
Post-Ischemic
Stroke


Learn about


Neuro-Diseases
Media
Facts

LEARNING PANEL


QUICK FACTS


Safety & Efficacy


A clinical trial evaluates a new medicine or treatment to see if it is safe and effective for patients


All approved medicines, even over-the-counter cold and pain medicines, have been tested in clinical trials


All clinical trials are monitored by ethical review boards to protect the safety of all participants


Governmental agencies review the results of trials to decide if new medicines or treatment are safe and effective and should be made available to the public


Do you or a loved one have..

What does it mean?

    This clinical trial is looking to reduce in the number of hours for patients experiencing "OFF" state when taking Tozadenant as an adjunctive therapy with Carbidopa/Levodopa

How long is the study?

    The study may involve 86 weeks, that is including the double-blind and open-lable treatment The time you will spend in the study will depend on the number of days you are able to complete

How to participate?

    Please take your time to make your decision about taking part. You may discuss your decision with your friends and family. You can also discuss it with your health care team. If you have any questions, you can ask your study doctor for more explanation.

You must be..

  • 30-80 of age
  • PD duration of at least 3 years from diagnosis.
  • experiencing end-of-dose “wearing-off” with at least 2.5 hours of OFF
  • be taking at least four doses of a levodopa-containing medication per day, and at least one other concomitant anti-PD medication (dopamine agonists, MAO-B inhibitors, anticholinergic agents, amantadine or entacapone).
  • But cannot be..

  • Known diagnosis of malignant melanoma.
  • Have hypertension with supine systolic BP ≥160
  • taking apomorphine, budipine, istradefylline, tolcapone, or DUOPA™/Duodopa®, within 4 weeks
  • have a moderate to severe hepatic or renal impairment
  • have moderate impulse control disorder
  •  

    if you are interested or someone you know that might be eligible, fill out our survey form here

    What does it mean?

      This clinical trial sponsored by Pfizer is looking to research motor fluctuations due to Parkinson's diesease and evaluate the effects of different doses of the study drug or placebo taken with your Levodopa (L-Dopa)

    How long is the study?

      The study may involve 15-weeks or more, that is including the double-blind and open-lable treatment The time you will spend in the study will depend on the number of days you are able to complete

    How to participate?

      Please take your time to make your decision about taking part. You may discuss your decision with your friends and family. You can also discuss it with your health care team. If you have any questions, you can ask your study doctor for more explanation.

    You must be..

  • 45-85 of age
  • PD duration of at least 3 years from diagnosis.
  • experiencing Total duration of 2.5 hours OFF time each day
  • On a stable dose of L-Dopa of at least 400 mg total daily dose for at least 28 days prior to Day 0 (Randomization)
  • But cannot be..

  • History of surgical intervention for Parkinson’s disease (pallidotomy, thalamotomy, deep brain stimulation, etc.).
  • Psychotic symptoms related to Parkinson’s disease requiring treatment with an antipsychotic medication within 6 months prior to Screening.
  • Currently receiving an antipsychotic, metoclopramide, reserpine, or amphetamine
  • A decrease in systolic blood pressure (BP) of >20 mmHg or in diastolic BP of >10 mmHg or severe Low blood pressure symptoms from standing
  • A positive test for hepatitis B surface antigen or hepatitis C antibody
  •  

    if you are interested or someone you know that might be eligible, fill out our survey form here

    What does it mean?

      A clinical study sponsored by Lundbeck recruiting patients with symptomatic neurogenic orthostatic hypotension to assess sustained effects Of Droxidopa therapy

    How long is the study?

      The study may involve 12-weeks or more, that is including the double-blind and open-lable treatment The time you will spend in the study will depend on the number of days you are able to complete

    How to participate?

      Please take your time to make your decision about taking part. You may discuss your decision with your friends and family. You can also discuss it with your health care team. If you have any questions, you can ask your study doctor for more explanation.

    You must be..

  • 18 years or older
  • Clinical diagnosis of symptomatic orthostatic hypotension associated with Primary Autonomic Failure (PD, MSA or PAF) or NDAN or DBH Deficiency
  • blood pressure drop of at least 20 mmHg in SBP, within 3 minutes of standing.
  • But cannot be..

  • Diagnosis of hypertension that requires treatment with antihypertensive medications
  • PAny specific uncontrolled cardiac arrhythmia
  • Diabetic autonomic neuropathy
  • History of cancer within the past 2 years other than a successfully treated, non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical cancer in situ
  • Gastrointestinal condition that may affect the absorption of Investigational Medicinal Product (e.g., ulcerative colitis, gastric bypass)
  •  

    if you are interested or someone you know that might be eligible, fill out our survey form here

    What does it mean?

      You or loved one have been previously treated for relapsing forms of Multiple Sclerosis (RMS).

    How long is the study?

      The study may involve 18 to 24 visits or more to the study site for up to 48 weeks. The time you will spend in the study will depend on the number of days you are able to complete. Approximately 24 men and women with RMS, ages 18 and over, may participate in this study.

    How to participate?

      Please take your time to make your decision about taking part. You may discuss your decision with your friends and family. You can also discuss it with your health care team. If you have any questions, you can ask your study doctor for more explanation.

    You must be..

  • 18-55 of age
  • ≥ 2 relapses in prior 2 years or 1 relapse in the year prior to screening and/or ≥1 Gd enhancing lesion
  • B cell counts ≥5% of total lymphocytes
  • Active disease
  • Neurologic stability ≥ 30 days prior to screening and baseline
  • Willingness and ability to comply with trial and follow-up procedures, give written consent
  • But cannot be..

  • Treatment with Anti-CD20 or other B cell directed treatment within last 12 months
  • Treated with alemtuzumab within the last 12 months prior to screening
  • Pregnant or nursing
  • Current evidence or known history of clinically significant infection including : a. Chronic or ongoing active infectious disease requiring long term systemic treatment such as, but not limited to: PML, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis (TB), or active hepatitis C b. Previous serious opportunistic or atypical infections c. History of positive serology for hepatitis B or HIV
  •  

    To learn more about this clinical trial.

    What does it mean?

      The main purpose of this study sponsored by Acorda Therapeutics, Inc is to see if taking dalfampridine-ER tablets twice daily is safe and has an effect on walking abilities in people who have had a stroke. This will be measured by tests of walking and balance, questionnaires, and routine safety tests.

    How long is the study?

      The study may involve 12 weeks and longer depending on if you participate on the open-lable phase, The time you will spend in the study will depend on the number of days you are able to complete

    How to participate?

      Please take your time to make your decision about taking part. You may discuss your decision with your friends and family. You can also discuss it with your health care team. If you have any questions, you can ask your study doctor for more explanation.

    You must be..

  • ≥ 6 months from occurrence of most recent ischemic stroke
  • 18 Years and older
  • evidence of a stable walking deficit due to an ischemic stroke, as judged by the Investigator
  • But cannot be..

  • History of seizures, except simple febrile seizures
  • Suicide attempt within 1 year prior to the Screening Visit, or severe suicidal ideation within 6 months prior to the Screening Visit, or subject is at significant risk of suicidal behavior in the opinion of the Investigator
  • Previous use of AMPYRA, dalfampridine, fampridine or 4-aminopyridine (4-AP)
  • Initiation of a serotonin reuptake inhibitor (SSRI) within 3 months prior to the Screening Visit, or any change in dosing regimen within 3 months prior to the Screening Visit
  • Botulinum toxin use within 2 months prior to the Screening Visit
  •  

    if you are interested or someone you know that might be eligible, fill out our survey form here

    What does it mean?

      The SERENE clinical research study is looking for people with Alzheimer's disease who have agitated and aggressive behaviour.

    How long is the study?

      If you volunteer and qualify for this study, your loved one will receive study medication for up to 12-weeks. During the study they will be asked to make regular visits to the clinic. His or her health is very important to us, and will be monitored throughout the study.

    How to participate?

      Please take your time to make your decision about taking part. You may discuss your decision with your friends and family. You can also discuss it with your health care team. If you have any questions, you can ask your study doctor for more explanation.

    You must be..

  • Age 50 or older
  • Diagonosed with Alzheimer's Disease
  • Showing agitated and aggressive behavior
  • Active disease
  • Willingness and ability to comply with trial and follow-up procedures, give written consent
  • Qualified volunteers will recieve

  • No-cost study medication for agitation/agression in patients with Alzheimer's Disease
  • No-cost-study-related medical care
  • Reimbursement for time and travel
  •  

    To learn more about this clinical trial.